Trials / Completed
CompletedNCT02873767
A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers
A Subject-Blind, Investigator-Blind, Randomized, Placebo-Controlled, First-In-Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of UCB4019 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate the safety and tolerability of single ascending doses of UCB4019 administered by subcutaneous injection in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PR1 | * Active substance: UCB4019 * Route of Administration: subcutaneously |
| OTHER | PL1 | * Active substance: Placebo * Concentration: 0.9 % saline * Route of Administration: subcutaneously |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2016-08-19
- Last updated
- 2017-02-09
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02873767. Inclusion in this directory is not an endorsement.